Acute Lymphoblastic Leukemia in Children and Adolescents

Inbunden, Engelska, 2024

2 459 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

This book is a comprehensive and up-to-date compendium on diagnosis, treatment and late effects of Acute Lymphoblastic Leukemia (ALL) in children, adolescents and young adults. After introductory chapters on the epidemiology and biology of ALL, treatment considerations are extensively reviewed, also with emphasis on special patient groups, such as Infants, Adolescents and patients with Down Syndrome. Immunotherapy in Acute Lymphoblastic Leukemia is reviewed as well as strategies for patients with Lymphoblastic Lymphoma and for patients with refractory or relapsed ALL. The authors are internationally recognized experts and offer up-to-date insights on etiology, biology, and treatment. This book will prove indispensable for those treating or researching into this disease.

Produktinformation

Utgivningsdatum2024-12-21
Mått178 x 254 x 27 mm
Vikt1 059 g
FormatInbunden
SpråkEngelska
SeriePediatric Oncology
Antal sidor397
FörlagSpringer International Publishing AG
ISBN9783031711794

Tillhör följande kategorier

Gabriele Escherich is working as a senior physician in pediatric hematology and oncology, head of outpatient clinic and day care clinic at the department of pediatric hematology and oncology, University medical center Hamburg-Eppendorf since 1992. For many years, research interest has focused on the treatment of children with acute lymphoblastic Leukemia. Since 2009 co-chair and since 2018 chair of the CoALL frontline trial for children with acute lymphoblastic leukemia mandated by the GPOH. As a board member of the ALLtogether consortium and national coordinator for Germany I had a significant influence on the development the first ALLtogether trial for the treatment of children and young adolescents with acute lymphoblastic leukemia. Beside this Gabriele Escherich is a member of the German Society of Pediatrics, the German Society of Pediatric Hematology and Oncology (GPOH) and the International Society of Pediatric Oncology (SIOP). Valentino Conter is working as a consultant in the pediatric hemato-oncology center of the IRCCS San Gerardo (Monza), Milano-Bicocca University. His research interest has focused mainly on the treatment of children with acute lymphoblastic Leukemia (ALL). He has been a member of the AIEOP (Italian Association of Pediatric Hemato-Oncology) ALL scientific committee since 1990, chair of the same committee from 2012 to 2018, principal investigator for AIEOP in the AIEOP-BFM (Berlin-Frankfurt-Münster) ALL 2009 study, and chair of the ALL Committee of the International BFM Study Group from 2004 till 2013. Valentino Conter has been involved since 1986 in outreach programs for pediatric hemato-oncology in low-middle income Countries and is a member of AIEOP and of the International Society of Pediatric Oncology (SIOP).

Part I: Epidemiology and Predisposition of ALL. Genetic predisposition for leukemia.- Association of leukemia with genetic diseases. Part II: Biology and Diagnostics of ALL. Genetic aberrations and profiles in Bcp ALL.- Genetic aberrations and profiles in T ALL.- Features of ALL in children, adolescents, and young adults.- Immunological Diagnosis.- MRD response: FCM, Ig/Tcr PCR, NGS. Part III: Stratification and treatment considerations in ALL. Stratification and treatment of Bcp ALL and T-ALL.- Stratification and treatment of Adolescents/AYA.- CNS therapy .- Stratification and treatment of Down Syndrome .- Stratification and treatment of Infants.- Stratification and treatment of BCR/ABL and ABL class fusion. Part IV: Immunotherapy in ALL. Immunotherapy with monoclonal antibodies.- Immunotherapy with CAR-T. Part V: Strategies for patients with Lymphoblastic Lymphoma/mature B-ALL. Stratification and treatment of lymphoblastic lymphomas.- Stratification and treatment of mature B ALLs. Part VI: Strategies for patients with refractory or relapsed ALL. Relapses: classification and treatment.- HSCT in 1rst CR and after subsequent CRs: indications, conditioning regimens. Part VII: Toxicity and Late effects following ALL treatment. Genetic disposition for toxicity Late toxicity including SMN.- late effects after HSCT. Part VIII: Perspectives and Future directions.- Global disparities in ALL treatment and outcome.- New agents.